US funding bill would tighten scrutiny on PBMs and more

21 January 2026

Congressional negotiators released a more than 1,000 page bipartisan government funding bill on Tuesday, racing a shutdown deadline of 30 January and aiming to avoid another lapse after last fall’s lengthy shutdown.

The package would provide $117 billion for the Department of Health and Human Services in 2026, a $210 million increase over 2025. It also contains Medicare-focused measures to curb pharmacy benefit managers’ ability to collect certain payments and to force more disclosure around rebates and patient out-of-pocket costs.

Within the Department of Health and Human Services, agencies that had been targeted for steep cuts under President Donald Trump’s proposals would largely be kept near current levels. The National Institutes of Health would receive $48.7 billion, broadly in line with fiscal 2025.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight



More Features in Pharmaceutical